Incyte Presents Results from a Phase I Trial of INCB024360; Achieves Greater Than 90% IDO1 Inhibition at Generally Well-tolerated Doses
Incyte Corporation (Nasdaq: INCY) presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. IDO1 expression in human tumors is associated with poor prognosis, and IDO1 inhibition may provide a new approach to increase survival in patients with a variety of solid tumors.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.